Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Follicum AB (publ)
  6. News
  7. Summary
    FOLLI   SE0006288270

FOLLICUM AB (PUBL)

(FOLLI)
  Report
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Follicum : reports revised top-line results from the Phase IIa study of FOL-005 for the treatment of hair loss (alopecia)

06/24/2021 | 04:50am EDT

Follicum AB (publ ) today reports revised top line data from a Phase IIa study of the tissue repairing peptide FOL-005 for the treatment of hair loss (alopecia). The revised data are based on an independent review that was conducted due to errors detected in the performance analysis presented by the Company on May 6, 2021. The revised results show no significant differences compared to what was previously reported and the Company stands by the decision to discontinue development of the product for the treatment of hair loss. However, Follicum will continue to explore opportunities to further develop FOL-005 in other disease areas.

"Having scrutinized the previously communicated study results, our conclusion remains that the company should not allocate additional resources to the development of FOL-005 for the treatment of hair loss. Instead, we will focus on our diabetes drug project, while evaluating other opportunities to utilize our tissue repairing peptides and our unique formulation technology in other disease areas", says Follicum's CEO, Kim Arvid Nielsen.

For further information, please contact:

Kim Arvid Nielsen - CEO, Follicum AB
Phone: +46 (0)70 392 1331
Email: kim.nielsen@follicum.com

This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact person above, for publication on the 24 June 2021.

About Follicum AB

Follicum AB (Spotlight: FOLLI) develops drugs based on tissue repair peptides with potential use in a range of diseaseareas. The company's most advanced drug candidate, FOL-005, is administered using a unique formulation technology found safe and well-tolerated in a comprehensive Phase 2 study conducted in collaboration with internationally renowned specialist clinics. In the field of diabetes, a project is being conducted that aims to protect insulin-producing cells from damage, thus reducing the risk for complications. The projects have the potential to become so-called first-in-class medicines. For more information, visit www.follicum.com.

https://news.cision.com/follicum/r/follicum-reports-revised-top-line-results-from-the-phase-iia-study-of-fol-005-for-the-treatment-of-h,c3373781

https://mb.cision.com/Main/12117/3373781/1436565.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about FOLLICUM AB (PUBL)
09/23BIOSTOCK : Coegin Pharma fuses with Swedish biotech Follicum
AQ
08/30FOLLICUM : har avslutat sin likviditetsgaranti från Sedermera Fondkommission rörande hande..
PU
08/26Follicum AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
06/24FOLLICUM : reports revised top-line results from the Phase IIa study of FOL-005 for the tr..
AQ
06/24Follicum AB Reports Revised Top-Line Results from the Phase IIa study of FOL-005 for th..
CI
06/03BIOSTOCK ARTICLE : Hopeful stock surge in Follicum after suspected analysis error in hair ..
PU
06/03BIOSTOCK : áHopeful stock surge in Follicum after suspected analysis error in hair loss pr..
AQ
05/20FOLLICUM : new CEO on the next steps in the company's development journey
PU
05/20Follicum AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
05/20BIOSTOCK : áFollicum's new CEO on the next steps in the company's development journey
AQ
More news
Financials
Sales 2020 0,21  0,02  0,02 
Net income 2020 -39,2 M -4,55 M -4,55 M
Net cash 2020 41,1 M 4,78 M 4,78 M
P/E ratio 2020 -5,32x
Yield 2020 -
Capitalization 31,9 M 3,70 M 3,70 M
EV / Sales 2019 -
EV / Sales 2020 993 131 610x
Nbr of Employees 4
Free-Float 100%
Chart FOLLICUM AB (PUBL)
Duration : Period :
Follicum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Kim Arvid Nielsen Chief Executive Officer
Jonas Erik Edelswńrd Chief Financial Officer
Gun-Britt Fransson Chairman
Jan Erik Alenfall Chief Scientific Officer
Maria Ekblad Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
FOLLICUM AB (PUBL)-87.00%4
MODERNA, INC.230.95%139 557
LONZA GROUP AG32.63%60 898
IQVIA HOLDINGS INC.42.93%48 923
SEAGEN INC.1.46%32 330
CELLTRION, INC.-38.02%26 036